Name: Designing the Modern Health Stack | Alex Karnal
Uploaded: 2026-04-21T12:00:58+00:00
Duration: 5897 s
Description: Designing the Modern Health Stack | Alex Karnal — AI-analyzed trade ideas from ILTB Podcast on Buzzberg.

Speakers

Alex Karnal — Partner, Andreessen Horowitz

Summary

Alex Karnal discusses the modern health stack, emphasizing GLP-1 drugs as a transformative class that proves the shift to proactive medicine. He covers PCSK9 inhibitors for cardiovascular health, Alzheimer's drugs, cancer screening, AI in drug discovery, and the peptide movement. He argues that we are on the cusp of a trillion-dollar revolution in healthcare that will extend lifespan and reduce costs.

GLP-1 drugs are a hundred billion dollar annual revenue opportunity and a proof point for proactive health.
PCSK9 inhibitors are a highly effective and underutilized class for cardiovascular protection.
Alzheimer's drugs from Biogen and Eli Lilly may show dramatic effects with early intervention.
Cancer screening companies like Exact Sciences and Guardant Health are improving early detection.
AI is accelerating drug discovery, with companies like Laya Sciences and Anaba leading.
Next-generation CAR-T therapies, such as Capstan's, show high efficacy.
The peptide movement and citizen pharmacology are emerging trends.
The health stack framework includes five defensive layers: lipid optimization, cardiometabolic health, neurocognitive health, inflammatory health, and blood pressure.

Trade Ideas

Alex Karnal Partner, Andreessen Horowitz 2:33

GLP-1 drugs are a massive revenue opportunity.

GLP-1 medicines are showing unprecedented adoption and have the potential to be a hundred billion dollar annual revenue class, representing the first commercial proof of a shift to proactive health. They address multiple layers of the health stack, including cardiometabolic health, weight loss, and cardiovascular risk reduction, with oral formulations and lower prices driving further adoption.

Alex Karnal Partner, Andreessen Horowitz 36:00

PCSK9 inhibitors are a free lunch for heart health.

PCSK9 inhibitors are a nearly free lunch for cardiovascular protection, lowering LDL cholesterol by 50% and reducing heart attack and stroke risk by over 20%. They have the potential to be bigger than GLP-1s in terms of patients and revenue because of their favorable risk-reward profile and the silent nature of high cholesterol.

Alex Karnal Partner, Andreessen Horowitz 46:55

Alzheimer's drugs from Biogen and Lilly are promising.

Anti-amyloid medicines from Biogen and Eli Lilly can break up plaques in the brain and, if given early, could dramatically slow cognitive decline. Data expected later in 2025 may show that early intervention could reduce decline by 40-50% or more.

Alex Karnal Partner, Andreessen Horowitz 52:14

Cancer screening companies are growing rapidly.

Companies like Exact Sciences and Guardant Health are advancing colorectal cancer screening with stool-based and blood tests, respectively, making screening more convenient and increasing adoption. Blood tests are inflecting and multi-cancer early detection tests are emerging, which could lead to earlier cancer detection and better outcomes.

Alex Karnal Partner, Andreessen Horowitz 57:24

Capstan's CAR-T therapy is highly effective.

Next-generation CAR-T therapies, such as those from Capstan, can be administered via IV without needing to extract cells, and they show dramatic efficacy in reducing tumors by 100% in a high percentage of patients for long periods.

Alex Karnal Partner, Andreessen Horowitz 65:25

AI drug discovery companies speed up development.

AI is accelerating drug discovery by enabling more comprehensive hypothesis generation and robotic experimentation. Companies like Laya Sciences and Anaba can go from model to molecule in a month instead of years, and those with novel data generation capabilities will build a moat.

Designing the Modern Health Stack | Alex Karnal

Summary

Trade Ideas

Up Next